NCT06208072View on ClinicalTrials.gov

The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

February 1, 2025

Conditions
Primary HypertensionObesity
Interventions
DRUG

Irbesartan 150mg

Irbesartan group will be treated with Irbesartan 150mg once daily for a total of 8 weeks.

DRUG

Eplerenone 25 mg

Eplerenone group will be treated with Eplerenone 25mg twice daily for a total of 8 weeks

Trial Locations (1)

115 27

RECRUITING

Hypertension Unit, A' University Cardiology Clinic, Hippocration General Hospital of Athens, Athens

All Listed Sponsors
collaborator

National and Kapodistrian University of Athens

OTHER

lead

Hippocration General Hospital

OTHER